532523 Stock Overview Engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Biocon Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Biocon Historical stock prices Current Share Price ₹362.55 52 Week High ₹404.60 52 Week Low ₹244.40 Beta 0.43 1 Month Change -1.69% 3 Month Change 14.05% 1 Year Change 31.98% 3 Year Change -7.41% 5 Year Change 17.50% Change since IPO 798.23%
Recent News & Updates
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Jan 31
Biocon Limited Announces Resignation of Mayank Verma as Company Secretary & Compliance Officer, with Effect from Close of Business Hours on April 14, 2025 Jan 30
Price target increased by 7.4% to ₹376 Jan 17
Price target increased by 8.2% to ₹371 Jan 14
Biocon Limited to Report Q3, 2025 Results on Jan 30, 2025 Jan 04
U.S. FDA Approves Biocon Biologics' YESINTEK, Bmab 1200 Biosimilar to J&J's Stelara (Ustekinumab) Dec 03 See more updates
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Jan 31
Biocon Limited Announces Resignation of Mayank Verma as Company Secretary & Compliance Officer, with Effect from Close of Business Hours on April 14, 2025 Jan 30
Price target increased by 7.4% to ₹376 Jan 17
Price target increased by 8.2% to ₹371 Jan 14
Biocon Limited to Report Q3, 2025 Results on Jan 30, 2025 Jan 04
U.S. FDA Approves Biocon Biologics' YESINTEK, Bmab 1200 Biosimilar to J&J's Stelara (Ustekinumab) Dec 03
New major risk - Financial position Nov 01
Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024) Oct 31
Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024 Oct 03
High number of new directors Aug 01
Full year 2024 earnings: EPS and revenues exceed analyst expectations Jul 22
Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 17
Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer Jun 13
Investor sentiment improves as stock rises 18% Jun 11
New minor risk - Earnings quality May 20
Dividend of ₹0.50 announced May 18
Biocon Limited, Annual General Meeting, Aug 09, 2024 May 18
Full year 2024 earnings: EPS and revenues exceed analyst expectations May 17
Investor sentiment improves as stock rises 17% Apr 26
Insider recently sold ₹5.3m worth of stock Apr 04
Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer Mar 15
Insider recently sold ₹3.3m worth of stock Feb 25
Insider recently sold ₹1.1m worth of stock Feb 20 Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 09
Investor sentiment improves as stock rises 17% Jan 05
Insider recently sold ₹1.8m worth of stock Jan 02
Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024 Dec 20
Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director Nov 30
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 12
Biocon Limited Announces Management Changes Oct 10
Insider recently sold ₹13m worth of stock Oct 05
Group Chief Information Officer recently sold ₹3.2m worth of stock Sep 22
Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer Sep 19
Insider recently sold ₹1.6m worth of stock Sep 01
Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director Aug 12
Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director Jul 27
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 23
New minor risk - Insider selling Jul 05
Upcoming dividend of ₹1.50 per share at 0.6% yield Jun 30
Insider recently sold ₹5.3m worth of stock Jun 02
Biocon Limited, Annual General Meeting, Aug 11, 2023 May 25
Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023 May 24
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 24
Insider recently sold ₹2.3m worth of stock Mar 29
Insider recently sold ₹1.1m worth of stock Mar 01
Price target decreased by 7.4% to ₹316 Feb 17
Biocon Plans to Sell Stake in Biologics Arm to Pare Debt Feb 17
Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022) Feb 15 Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023
Biocon Limited to Report Q3, 2023 Results on Feb 14, 2023 Jan 07
Insider recently sold ₹13m worth of stock Jan 05
Insider recently sold ₹40m worth of stock Dec 22 Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis Dec 17
Insider recently sold ₹4.2m worth of stock Nov 30
Biocon Limited Announces Board Changes Nov 16
Second quarter 2023 earnings released: EPS: ₹0.39 (vs ₹1.16 in 2Q 2022) Nov 16
Biocon Limited to Report Q2, 2023 Results on Nov 14, 2022 Oct 21
Insider recently sold ₹4.1m worth of stock Sep 30
Insider recently sold ₹3.8m worth of stock Aug 19
Price target decreased to ₹379 Aug 15
Biocon Limited Announces Directors Resignation Jul 29
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Jul 07 Biocon Limited to Report Q3, 2023 Results on Jan 24, 2023
Biocon Limited to Report Q1, 2023 Results on Jul 27, 2022 Jul 02
Biocon Limited (NSEI:BIOCON) agreed to acquire 26% stake in AMPYR Renewable Energy Resources Eleven Private Limited for INR 75 million. Jun 30
Upcoming dividend of ₹0.50 per share Jun 23
Now 20% undervalued after recent price drop May 25
Chief Human Resources Officer recently sold ₹1.3m worth of stock May 22
Chief Human Resources Officer recently sold ₹1.8m worth of stock May 12
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 01
Insider recently sold ₹2.2m worth of stock Apr 03
Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio Mar 07
Investor sentiment deteriorated over the past week Mar 04
Insider recently sold ₹1.6m worth of stock Feb 26
Insider recently sold ₹6.8m worth of stock Feb 05
Price target increased to ₹399 Jan 24
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Jan 22
Biocon Reportedly in Talks with Mylan to Merge Biosimilar Businesses Dec 09
Insider recently sold ₹4.7m worth of stock Dec 09
Insufficient new directors Dec 06
Chief Human Resources Officer recently sold ₹1.8m worth of stock Nov 20
Chief Human Resources Officer recently sold ₹7.0m worth of stock Nov 10
Insider recently sold ₹1.0m worth of stock Nov 04
Second quarter 2022 earnings released: EPS ₹1.16 (vs ₹1.47 in 2Q 2021) Oct 23
Chief Human Resources Officer recently sold ₹2.6m worth of stock Oct 03
Chief Human Resources Officer recently sold ₹1.1m worth of stock Sep 29
Insider recently sold ₹2.3m worth of stock Sep 16
Non-Executive Vice Chairman John Shaw has left the company Jul 25
Full year 2021 earnings released: EPS ₹6.32 (vs ₹6.56 in FY 2020) Jul 03
Full year 2021 earnings released: EPS ₹6.32 (vs ₹6.32 in FY 2020) May 02
President of Human Resources recently sold ₹1.2m worth of stock Mar 31 Shareholder Returns 532523 IN Biotechs IN Market 7D -6.7% -10.1% -1.8% 1Y 32.0% 33.1% 6.2%
See full shareholder returns
Return vs Market: 532523 exceeded the Indian Market which returned 6.2% over the past year.
Price Volatility Is 532523's price volatile compared to industry and market? 532523 volatility 532523 Average Weekly Movement 6.0% Biotechs Industry Average Movement 6.3% Market Average Movement 6.3% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.3%
Stable Share Price: 532523 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532523's weekly volatility (6%) has been stable over the past year.
About the Company Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab.
Show more Biocon Limited Fundamentals Summary How do Biocon's earnings and revenue compare to its market cap? 532523 fundamental statistics Market cap ₹433.90b Earnings (TTM ) ₹8.04b Revenue (TTM ) ₹151.16b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 532523 income statement (TTM ) Revenue ₹151.16b Cost of Revenue ₹57.38b Gross Profit ₹93.78b Other Expenses ₹85.74b Earnings ₹8.04b
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) 6.72 Gross Margin 62.04% Net Profit Margin 5.32% Debt/Equity Ratio 60.4%
How did 532523 perform over the long term?
See historical performance and comparison Dividends
0.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 20:59 End of Day Share Price 2025/01/31 00:00 Earnings 2024/12/31 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Biocon Limited is covered by 48 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Meeta Shetty Asian Markets Securities Private Limited Harith Ahamed Avendus Spark Vijayaraghavan Swaminathan Avendus Spark
Show 45 more analysts 
